A cutting edge overview: Psoriatic disease

Clinical Reviews in Allergy and Immunology

Volumn 44, Issue 2, 2013, Pages 109-113

  Raychaudhuri, Siba P ^a,b  

^a VA Sacramento Medical Centre   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologics; Epidemiology; Imaging; Inflammation; Psoriasis; Psoriatic arthritis

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; GROWTH FACTOR; NEUROPEPTIDE; T LYMPHOCYTE RECEPTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EPIDERMIS; GENETICS; HUMAN; INFLAMMATION; KERATINOCYTE; PATHOGENESIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; T LYMPHOCYTE;

EID: 84879374570     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8309-z     Document Type: Review

References (82)

1. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866-873
2. Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210-212 (Pubitemid 43209292)
3. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735-1741 (Pubitemid 44547793)
4. Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895-802
5. Stuart PE, Nair RP, Ellinghaus E et al (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000-1004
6. Nickoloff BJ, Schröder JM, von den Driesch P et al (2000) Is psoriasis a T-cell disease? Exp Dermatol 9:359-375
7. Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314-J321
8. Nickoloff BJ (2006) Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12:102-106
9. Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263-271 (Pubitemid 47069537)
10. Hertle MD, Kubler MD, Leigh IM, Watt FM (1992) Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89:1892-1901
11. Sa SM, Valdez PA, Wu J et al (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229-2240 (Pubitemid 46233421)
12. Wolk K, Witte E, Warszawska K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570-3581
13. Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) L-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359:419-429
14. Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961-971 (Pubitemid 351519993)
15. Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB (1999) Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79:9-11 (Pubitemid 29079320)
16. Romanowska M, al Yacoub N, Seidel H et al (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128:110-124 (Pubitemid 350249370)
17. Széles L, Töröcsik D, Nagy L (2007) PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014-1030 (Pubitemid 47202035)
18. al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940-1949 (Pubitemid 352001216)
19. Sagoo GS, Tazi-Ahnini R, Barker JW et al (2004) Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 122:1401-1405 (Pubitemid 38757221)
20. Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110:958-960 (Pubitemid 28237704)
21. Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38:7-13 (Pubitemid 32102316)
22. Capon F, Semprini S, Chimenti S et al (2001) Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116:728-730 (Pubitemid 32467651)
23. Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199-204
24. Zhang XJ, Huang W, Yang S et al (2009) Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41:205-210
25. Campalani E, Allen MH, Fairhurst D et al (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154:345-352 (Pubitemid 43382709)
26. Gottlieb AB, Lebwohl M, Shirin S et al (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595-504
27. Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887 (Pubitemid 26359206)
28. Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573-3585
29. Caruso R, Botti E, Sarra M et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013-1015
30. Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339-1350
31. Shibata S, Tada Y, Kanda N et al (2010) Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 130:1034-1039
32. Lowes MA, Chamian F, Abello MV et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci 102:19057-19062 (Pubitemid 43049565)
33. Wang H, Peters T, Kess D et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105-2114 (Pubitemid 44162319)
34. Braverman IM, Yen A (1977) Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68:53-60 (Pubitemid 8019017)
35. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 42:1481-1484 (Pubitemid 30265607)
36. Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231-236 (Pubitemid 36875122)
37. Libby P, Paul M, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143 (Pubitemid 34212626)
38. Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251-266 (Pubitemid 30145535)
39. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331-334
40. Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736-1744 (Pubitemid 47110373)
41. Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5:230-233 (Pubitemid 43668458)
42. Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178-J206
43. Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251-A258
44. Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34:380-384
45. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247-J257
46. Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276-J286
47. Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9:A247-A250
48. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163-J167
49. Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267-A270
50. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168-J177
51. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325-330
52. Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9:A271-A276
53. Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288-A292
54. Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293-A298
55. Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325-A329
56. Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400-A405
57. Round JL, O'Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220-J225
58. Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335-A341
59. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity - autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259-A266
60. Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372-A378
61. Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379-A382
62. Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226-J233
63. Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287-J299
64. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277-A287
65. Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355-A365
66. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207-J219
67. Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234-J246
68. Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258-J265
69. Langham S, Langham J, Goertz HP, Ratcliffe M (2011) Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systemic and critical review. BMC Med Res Methodol 11:32
70. Slutsky JB, Clark RA, Remedios AA, Klein PA (2010) An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 9:1258-1264
71. O'Neill JL, Feldman SR (2010) Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 46:351-360
72. Seminara NM, Gelfand JM (2010) Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 29:16-19
73. Baraliakos X, Braun J (2010) Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 6:9-19
74. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273-288
75. Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P, Poilani PL, Burocchi A, Passafaro AL, Gorzanelli A, Vitali C, Chiodoni C, Barnaba V, Pedotti R, Colombo MP (2011) The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 37:300-310
76. Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, Nussenblatt RB, Philip McCoy J Jr (2011) MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun 37:319-327
77. Kaminski S, Hermann-Kleiter N, Meisel M, Thuille N, Cronin S, Hara H, Fresser F, Penninger JM, Baier G (2011) Coronin 1A is an essential regulator of the TGFβ receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. J Autoimmun 37:198-208
78. Wang YL, Chou FC, Chen SJ, Lin SH, Chang DM, Sytwu HK (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - an unrevealed role in downregulation of Th17 cells. J Autoimmun 37:160-170
79. Baugh M, Black D, Westwood P, Kinghorn E et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201-209
80. Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65-75
81. Oo YH, Adams DH (2010) The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 34:45-54
82. Reich A, Szepietowski JC (2011) Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 12:313-320